Risk of relapse and readmission among hospitalized adults with carbapenem non-susceptible gram-negative infections

References

• Cars O. Securing access to effective antibiotics for current and future generations. Whose responsibility? Ups J Med Sci. 2014;119(2):209–214.
   PubMed Web of Science ®Google Scholar
• Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013;34(1):1–14.
   PubMed Web of Science ®Google Scholar
• Exner M, Bhattacharya S, Christiansen B, et al. Antibiotic resistance: What is so special about multidrug-resistant gram-negative bacteria? GMS Hyg Infect Control. 2017;12:doc05.
   PubMed Web of Science ®Google Scholar
• US Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. 2019; [cited 2020 Sep 25]. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.
   Google Scholar
• Thorpe KE, Joski P, Johnston KJ. Antibiotic-Resistant infection treatment costs have doubled since 2002, now exceeding $2 billion annually. Health Aff. 2018;37(4):662–669.
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Endimiani A, Taracila MA, et al. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943–4960.
   PubMed Web of Science ®Google Scholar
• Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15–21.
   PubMed Web of Science ®Google Scholar
• Rhodes NJ, Wagner JL, Davis SL, et al. Trends in and predictors of carbapenem consumption across North American hospitals: results from a multicenter survey by the MAD-ID research network. Antimicrob Agents Chemother. 2019;63(7):19.
   Web of Science ®Google Scholar
• Bartsch SM, McKinnell JA, Mueller LE, et al. Potential economic burden of carbapenem-resistant enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect. 2017;23(1):e16.48.
   Web of Science ®Google Scholar
• Babiker A, Clarke LG, Saul M, et al. Changing epidemiology and decreased mortality associated with Carbapenem-resistant Gram-negative bacteria from 2000 to 2017. Clin Infect Dis. 2020;73(11):e4521–e4530.
   Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, et al. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis. 2017;17(1):279.
   PubMedGoogle Scholar
• Kadri SS, Lai YL, Warner S, et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis. 2021;21(2):241–251.
   PubMed Web of Science ®Google Scholar
• Raman G, Avendano E, Berger S, et al. Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis. BMC Infect Dis. 2015;15:395.
   PubMed Web of Science ®Google Scholar
• Zasowski EJ, Bassetti M, Blasi F, et al. A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial infections. Chest. 2020;158(3):929–938.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, et al. 30-day readmission, antibiotics costs and costs of delay to adequate treatment of enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study. Antimicrob Resist Infect Control. 2017;6:124.
   PubMed Web of Science ®Google Scholar
• Tabak YP, Sung A, Ye G, et al. Attributable burden in patients with carbapenem-nonsusceptible gram-negative respiratory infections. PLoS One. 2020;15(2):e0229393.
   PubMed Web of Science ®Google Scholar
• Muggeo A, Guillard T, Barbe C, et al. Factors associated with carriage of carbapenem-non-susceptible enterobacteriaceae in North-Eastern France and outcomes of infected patients. J Antimicrob Chemother. 2017;72(5):1496–1501.
   PubMed Web of Science ®Google Scholar
• Wu PF, Chuang C, Su CF, et al. High minimum inhibitory concentration of imipenem as a predictor of fatal outcome in patients with carbapenem non-susceptible Klebsiella pneumoniae. Sci Rep. 2016;6:32665.
   PubMed Web of Science ®Google Scholar
• Mataseje LF, Abdesselam K, Vachon J, et al. Results from the Canadian nosocomial infection surveillance program on carbapenemase-producing enterobacteriaceae, 2010 to 2014. Antimicrob Agents Chemother. 2016;60(11):6787–6794.
   PubMed Web of Science ®Google Scholar
• Sheu CC, Chang YT, Lin SY, et al. Infections caused by carbapenem-resistant enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019;10:80.
   PubMed Web of Science ®Google Scholar
• Papst L, Beovic B, Pulcini C, et al. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect. 2018;24(10):1070–1076.
   PubMed Web of Science ®Google Scholar
• Carrara E, Bragantini D, Tacconelli E. Combination versus monotherapy for the treatment of infections due to carbapenem-resistant enterobacteriaceae. Curr Opin Infect Dis. 2018;31(6):594–599.
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943–950.
   PubMed Web of Science ®Google Scholar
• Agyeman AA, Bergen PJ, Rao GG, et al. A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. Int J Antimicrob Agents. 2020;55(1):105833.
   PubMed Web of Science ®Google Scholar
• Kaye KS, Marchaim D, Thamlikitkul MD, et al. Colistin monotherapy versus combination therapy for carbapenem-resistant organisms. NEJM Evid. 2022;2(1). DOI:10.1056/EVIDoa2200131
   Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400.
   PubMed Web of Science ®Google Scholar
• Nutman A, Lellouche J, Temkin E, et al. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. Clin Microbiol Infect. 2020;26(9):1185–1191.
   PubMed Web of Science ®Google Scholar
• Palacios-Baena ZR, Giannella M, Manissero D, et al. Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. Clin Microbiol Infect. 2021;27(2):228–235.
   PubMed Web of Science ®Google Scholar
• Raman G, Avendano EE, Chan J, et al. Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2018;7:79.
   PubMed Web of Science ®Google Scholar
• Carreno JJ, Tam IM, Meyers JL, et al. Jr. Longitudinal, nationwide cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection. Open Forum Infect Dis. 2019;2019:446.
   Google Scholar
• Babich T, Eliakim-Raz N, Turjeman A, et al. Risk factors for hospital readmission following complicated urinary tract infection. Sci Rep. 2021;11(1):6926.
   PubMed Web of Science ®Google Scholar
• Wilson APR. Sparing carbapenem usage. J Antimicrob Chemother. 2017;72(9):2410–2417.
   PubMed Web of Science ®Google Scholar
• Bradley EH, Curry L, Horwitz LI, et al. Hospital strategies associated with 30-day readmission rates for patients with heart failure. Circ Cardiovasc Qual Outcomes. 2013;6(4):444–450.
   PubMed Web of Science ®Google Scholar
• Koehler BE, Richter KM, Youngblood L, et al. Reduction of 30-day postdischarge hospital readmission or emergency department (ED) visit rates in high-risk elderly medical patients through delivery of a targeted care bundle. J Hosp Med. 2009;4(4):211–218.
   PubMed Web of Science ®Google Scholar